Psychedelic Investor Survey Q3 2025: investor sentiment rises with new US administration, plus capital allocation and priorities

Psychedelic Investor Survey Q3 2025 reports investor sentiment and allocation trends for the psychedelics sector, based on 182 respondents. Across the survey, retail participation has rebounded relative to the prior year, but ticket sizes did not shift toward many smaller commitments. Investors report more optimism than in Q3 2024, with more than half now moderately to highly optimistic and fewer respondents expressing neutral or pessimistic views. The survey ties this sentiment lift largely to changes in the US political and regulatory landscape. Investors continue to find drug discovery and development the most attractive value chain segment, while manufacturing and CPG and adult-use are rated more unattractive. Looking ahead, most plan to invest the same or greater capital in the next 12 months, and many remain willing to wait more than three years for returns. Regulatory hurdles remain the dominant concern, alongside worries about commercialization details like rollout and reimbursement pathways. The report also covers investors' self-reported personal psychedelic use (slightly down) and the sustainability of interest, where nearly half say current interest is entirely sustainable, the highest share recorded.